STOCK TITAN

Andrew Callos reports multiple 10b5-1 sales for CYTK (NASDAQ: CYTK)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Morgan Stanley Smith Barney LLC filed a Form 144 disclosing resale notices for Common stock related to multiple 10b5-1 sales attributed to Andrew Callos. The filing lists dated sales and per‑trade quantities with associated cash amounts, including 03/05/2026 sales of 15,000 and 11,000 shares.

Positive

  • None.

Negative

  • None.

Insights

Routine resale notices under Rule 144 documenting several 10b5-1 sales.

The filing lists multiple executed sales of Common stock under prearranged 10b5-1 plans, with individual trades showing share counts and gross cash amounts (for example, $928,062.00 for 03/05/2026). The notice is procedural and records transactions rather than new company actions.

Cash‑flow treatment and any proceeds recipients are explicit in the trade lines; the filing does not state additional conditions or changes to ownership limits. Subsequent filings or Form 4s would be needed to update post‑transaction positions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does CYTK's Form 144 disclose about Andrew Callos?

It discloses multiple resale notices for Common stock executed under 10b5-1 plans. The filing lists dated trades with share counts and amounts, including 03/05/2026 sales of 15,000 and 11,000 shares and associated cash figures.

Are the transactions in CYTK's Form 144 open‑market sales or plan sales?

The filing identifies the trades as 10b5-1 sales. Each line is labeled as a 10b5-1 sale with trade dates, share quantities, and gross proceeds; the notice documents prearranged plan executions rather than ad hoc market purchases.

Does CYTK's Form 144 state who receives the sale proceeds?

Each trade line shows a cash amount but does not restate proceeds recipient separately. The filing records gross cash amounts per sale (for example, $928,062.00) without additional allocation or use-of-proceeds language in the excerpt.

Will CYTK’s Form 144 change reported ownership on its own?

No—Form 144 is a resale notice and does not by itself update post‑transaction holdings. Position changes are typically reflected in Form 4 or other ownership disclosures; this filing documents the sales that occurred under 10b5-1 arrangements.

Which dates and sizes are prominent in the CYTK Form 144 excerpt?

Multiple trades span late 2025 to March 2026. Notable entries include 01/05/2026 for 15,000 shares ($904,165.50) and 03/05/2026 trades of 15,000 and 11,000 shares with respective amounts shown.
Cytokinetics Inc

NASDAQ:CYTK

View CYTK Stock Overview

CYTK Rankings

CYTK Latest News

CYTK Latest SEC Filings

CYTK Stock Data

7.66B
120.48M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO